New diabetes drug shows promise in chinese trial
NCT ID NCT02916706
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called teneligliptin in 254 Chinese adults with type 2 diabetes. Half received the drug and half received a placebo for 24 weeks. The main goal was to see if teneligliptin lowers blood sugar levels (HbA1c) better than a placebo. Researchers also checked fasting blood sugar and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Teneligliptin
- What this could lead to
- If successful, this could provide a new oral medication option to help control blood sugar in people with type 2 diabetes.
- What could go wrong
- This is a completed Phase 3 trial, but results may not apply to all populations. Teneligliptin is already approved in some countries, so the benefit here is confirmatory rather than groundbreaking.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigational center
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a blood flow 'Tourniquet' workout repair diabetic nerve damage?
- Could a common diabetes drug weaken your bones?
- Can a spice and a mindset shift ease diabetic nerve pain?
- Ancient wisdom meets modern care: could chinese medicine boost diabetes Self-Management?
- Could a peptide injection help rebuild Insulin-Making cells?
- A pill for diabetes? new oral drug aims to rival injections